{"id":53974,"date":"2021-07-31T17:25:02","date_gmt":"2021-07-31T21:25:02","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/?p=53974"},"modified":"2023-06-06T18:12:41","modified_gmt":"2023-06-06T22:12:41","slug":"advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/","title":{"rendered":"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status"},"content":{"rendered":"<figure id=\"attachment_53977\" class=\"thumbnail wp-caption alignright\" style=\"width: 310px\"><a href=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-53977\" src=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-300x267.png\" alt=\"\" width=\"300\" height=\"267\" srcset=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-300x267.png 300w, https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-768x682.png 768w, https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-600x533.png 600w, https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-301x267.png 301w, https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png 880w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><figcaption class=\"caption wp-caption-text\">Tracey Rose, MD, MPH, and William Kim, MD<\/figcaption><\/figure>\n<p>A new study demonstrates patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is similar to patients without that mutation, a discovery that runs counter to previous assumptions. Led by scientists in the Department of Medicine and members of the Lineberger Comprehensive Cancer Center, the study has important implications for patients who have not been offered immunotherapy because of their genetic profiles.<\/p>\n<p>\u201cClinical trials have shown that bladder cancers with FGFR3 mutations have fewer immune cells, primarily T cells, than cancers without the mutation, said <a href=\"https:\/\/www.med.unc.edu\/medicine\/directory\/tracy-rose\/\">Tracy Rose<\/a>, MD, MPH, assistant professor in the division of oncology, and the paper\u2019s co-first author, in <a href=\"https:\/\/oncologynews.com.au\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\"><em>Oncology News<\/em><\/a>. &#8220;Because tumors with low levels of immune cells tend to respond poorly to immune checkpoint blockades, it has been hypothesized that those patients would have low response rates to immunotherapy.\u201d<\/p>\n<p>Rose and <a href=\"https:\/\/www.med.unc.edu\/medicine\/directory\/william-y-kim\/\">William Y. Kim<\/a>, MD, the Rush S. Dickson Distinguished Professor of Medicine and professor of Genetics, designed the study to compare tumor tissue samples and clinical trials data from 17 patients with FGFR3-mutated bladder cancer to 86 patients whose tumors did not have the mutation. The investigators found that patients with FGFR3 mutations responded to immunotherapy equally as well as those without the mutations.<\/p>\n<p>The paper was published in the <a href=\"https:\/\/www.nature.com\/articles\/s41416-021-01488-6\" target=\"_blank\" rel=\"noopener noreferrer\"><em>British Journal of Cancer<\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study demonstrates patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is similar to patients without that mutation, a discovery that runs counter to previous assumptions. Led by scientists in the Department of Medicine and members of the Lineberger Comprehensive Cancer Center, &hellip; <a href=\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\" aria-label=\"Read more about Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status\">Read more<\/a><\/p>\n","protected":false},"author":69419,"featured_media":53977,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,517],"tags":[630],"class_list":["post-53974","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-oncology","tag-630","odd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status | Department of Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status | Department of Medicine\" \/>\n<meta property=\"og:description\" content=\"A new study demonstrates patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is similar to patients without that mutation, a discovery that runs counter to previous assumptions. Led by scientists in the Department of Medicine and members of the Lineberger Comprehensive Cancer Center, &hellip; Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Medicine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UNCDeptMedicine\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-31T21:25:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-06T22:12:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png\" \/>\n\t<meta property=\"og:image:width\" content=\"880\" \/>\n\t<meta property=\"og:image:height\" content=\"782\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Kim Morris\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:site\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Morris\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\"},\"author\":{\"name\":\"Kim Morris\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"headline\":\"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status\",\"datePublished\":\"2021-07-31T21:25:02+00:00\",\"dateModified\":\"2023-06-06T22:12:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\"},\"wordCount\":247,\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png\",\"keywords\":[\"2021\"],\"articleSection\":[\"News\",\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\",\"name\":\"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status | Department of Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png\",\"datePublished\":\"2021-07-31T21:25:02+00:00\",\"dateModified\":\"2023-06-06T22:12:41+00:00\",\"author\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png\",\"width\":880,\"height\":782,\"caption\":\"Tracey Rose, MD, and William Kim, MD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/\",\"name\":\"Department of Medicine\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529\",\"name\":\"Kim Morris\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g\",\"caption\":\"Kim Morris\"},\"description\":\"Medicine - Dept of\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status | Department of Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/","og_locale":"en_US","og_type":"article","og_title":"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status | Department of Medicine","og_description":"A new study demonstrates patients with advanced bladder cancers whose tumors have a mutated FGFR3 gene respond to immunotherapy treatment in a manner that is similar to patients without that mutation, a discovery that runs counter to previous assumptions. Led by scientists in the Department of Medicine and members of the Lineberger Comprehensive Cancer Center, &hellip; Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/","og_site_name":"Department of Medicine","article_publisher":"https:\/\/www.facebook.com\/UNCDeptMedicine","article_published_time":"2021-07-31T21:25:02+00:00","article_modified_time":"2023-06-06T22:12:41+00:00","og_image":[{"width":880,"height":782,"url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png","type":"image\/png"}],"author":"Kim Morris","twitter_card":"summary_large_image","twitter_creator":"@uncdeptmedicine","twitter_site":"@uncdeptmedicine","twitter_misc":{"Written by":"Kim Morris","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/"},"author":{"name":"Kim Morris","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"headline":"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status","datePublished":"2021-07-31T21:25:02+00:00","dateModified":"2023-06-06T22:12:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/"},"wordCount":247,"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png","keywords":["2021"],"articleSection":["News","Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/","url":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/","name":"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status | Department of Medicine","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png","datePublished":"2021-07-31T21:25:02+00:00","dateModified":"2023-06-06T22:12:41+00:00","author":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529"},"breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#primaryimage","url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png","contentUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png","width":880,"height":782,"caption":"Tracey Rose, MD, and William Kim, MD"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/advanced-bladder-cancers-respond-to-immunotherapy-regardless-of-gene-mutation-status\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/"},{"@type":"ListItem","position":2,"name":"Advanced Bladder Cancers Respond to Immunotherapy Regardless of Gene Mutation Status"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/","name":"Department of Medicine","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/9a358414a53d5237f9ba3f8daa55c529","name":"Kim Morris","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/95c34b3e4d55a602b94260bccc6350c2ddfdde901530a734fe6c8fa9e3a5d399?s=96&d=mm&r=g","caption":"Kim Morris"},"description":"Medicine - Dept of","url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/kcmorris\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png","featured_image_medium":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-300x267.png","featured_image_medium_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-768x682.png","featured_image_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim.png","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2021\/07\/rose-kim-150x150.png","featured_image_alt":"rose-kim","category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/news\/"},{"name":"Oncology","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/oncology\/"}],"tag_details":[{"name":"2021","link":"https:\/\/www.med.unc.edu\/medicine\/news\/tag\/2021\/"}],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/53974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/users\/69419"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/comments?post=53974"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/53974\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media\/53977"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media?parent=53974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/categories?post=53974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/tags?post=53974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}